Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
Amid sales slump, Teva CEO Schultz's pay falls 7% to $14.7M | Fierce Pharma
Teva CEO Vigodman Steps Down After Poor Outlook for 2017 | Fortune
Teva Pharmaceutical CEO on Bringing His Company Back from the Brink | Barron's
Watch Teva Makes Mylan Bid for $82 per Share - Bloomberg
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York state - Local News 8
Teva Is Exploring Mylan Bid to Create Generic-Drug Giant - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC - TheStreet
Teva's U.S. Unit Charged in Generic-Drug Price-Fixing Probe
Watch How to Trade Teva Pharmaceutical - Bloomberg
Teva to Cut Up to 25% of Israel Workforce, Calcalist Says - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%
Teva's $225 Million Opioid Deal With Texas Is Its Biggest (2)
Israel's Teva offering free drugs to settle U.S. opiods case - Business - Haaretz.com
Teva Abandons Search to Make Covid-19 Vaccine for Partners - Bloomberg
Kare Schultz, president and chief executive officer of Teva... News Photo - Getty Images
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Glaxo/Teva Ruling Could Spell Trouble for Generic Drugmakers
TEVA: Teva Pharmaceutical Industries Ltd Stock Price Quote - New York - Bloomberg
Watch Mylan Board Rejects $40.1B Teva Takeover Bid - Bloomberg
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
